JP2024524363A5 - - Google Patents
Info
- Publication number
- JP2024524363A5 JP2024524363A5 JP2023580402A JP2023580402A JP2024524363A5 JP 2024524363 A5 JP2024524363 A5 JP 2024524363A5 JP 2023580402 A JP2023580402 A JP 2023580402A JP 2023580402 A JP2023580402 A JP 2023580402A JP 2024524363 A5 JP2024524363 A5 JP 2024524363A5
- Authority
- JP
- Japan
- Prior art keywords
- linker
- drug compound
- formula
- compound according
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21182160 | 2021-06-28 | ||
| EP21182160.8 | 2021-06-28 | ||
| PCT/EP2022/067693 WO2023275025A1 (en) | 2021-06-28 | 2022-06-28 | Conjugates comprising phosphoantigens and their use in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524363A JP2024524363A (ja) | 2024-07-05 |
| JP2024524363A5 true JP2024524363A5 (https=) | 2025-07-02 |
Family
ID=76695639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580402A Pending JP2024524363A (ja) | 2021-06-28 | 2022-06-28 | ホスホ抗原を含む複合体及び治療における使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240261426A1 (https=) |
| EP (1) | EP4362982A1 (https=) |
| JP (1) | JP2024524363A (https=) |
| KR (1) | KR20240027761A (https=) |
| CN (1) | CN117794581A (https=) |
| AU (1) | AU2022302784A1 (https=) |
| BR (1) | BR112023026735A2 (https=) |
| CA (1) | CA3223936A1 (https=) |
| CL (1) | CL2023003905A1 (https=) |
| IL (1) | IL309249A (https=) |
| MX (1) | MX2023014899A (https=) |
| WO (1) | WO2023275025A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120379696A (zh) | 2022-12-22 | 2025-07-25 | 拜奥迪斯私人有限公司 | 包含磷酸抗原的新的接头药物、新的缀合物及其在治疗中的用途 |
| WO2026080697A1 (en) * | 2024-10-09 | 2026-04-16 | Sutro Biopharma, Inc. | Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| FI115001B (fi) | 2003-07-11 | 2005-02-15 | Metso Paper Inc | Menetelmä ja sovitelma rullan päätylapun sijainnin mittaamiseksi |
| JP4942643B2 (ja) | 2004-03-02 | 2012-05-30 | シアトル ジェネティックス， インコーポレイテッド | 部分的に付加された抗体およびそれらの結合体化方法 |
| ATE419008T1 (de) * | 2004-04-26 | 2009-01-15 | Innate Pharma | Adjuvante zusammensetzung und anwendungsverfahren dafür |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| EP1948195A2 (en) * | 2005-11-17 | 2008-07-30 | Innate Pharma | Improved methods of using phosphoantigen for the treatment of cancer |
| WO2008059052A1 (en) * | 2006-11-17 | 2008-05-22 | Innate Pharma | Improved methods of using phosphoantigen for the treatment of cancer |
| WO2009152440A1 (en) * | 2008-06-13 | 2009-12-17 | Cedars-Sinai Medical Center | Small molecule ligand-drug conjugates for targeted cancer therapy |
| WO2010049438A2 (en) * | 2008-10-30 | 2010-05-06 | Innate Pharma | Improved methods of using phosphoantigens for the treatment of diseases |
| ES2647317T3 (es) | 2008-11-03 | 2017-12-20 | Syntarga B.V. | Análogos de CC-1065 y sus conjugados |
| PT3056203T (pt) | 2010-04-21 | 2018-02-15 | Syntarga Bv | Conjugados de análogos de cc-1065 e ligantes bifuncionais |
| IT1401882B1 (it) | 2010-10-01 | 2013-08-28 | Rosa De | Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori. |
| HUE033704T2 (en) | 2012-02-13 | 2017-12-28 | Bristol Myers Squibb Co | Enediyne compounds, conjugates thereof, and uses and methods therefor |
| CN110947002A (zh) * | 2012-05-01 | 2020-04-03 | 约翰霍普金斯大学 | 治疗或预防骨关节炎的组合物和方法 |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| SG11201609372UA (en) | 2014-05-22 | 2016-12-29 | Synthon Biopharmaceuticals Bv | Site-specific conjugation of linker drugs to antibodies and resulting adcs |
| EP3368092B9 (en) | 2015-10-29 | 2020-07-29 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
| CA3026139C (en) | 2016-02-12 | 2023-09-12 | Synthon Biopharmaceuticals B.V. | Selective reduction of cysteine-engineered antibodies |
| US11419944B2 (en) | 2016-10-11 | 2022-08-23 | Byondis B.V. | Non-linear self-immolative linkers and conjugates thereof |
| US11696958B2 (en) | 2017-05-23 | 2023-07-11 | Byondis B.V. | Dual conjugation process for preparing antibody-drug conjugates |
| WO2019182904A1 (en) | 2018-03-19 | 2019-09-26 | University Of Iowa Research Foundation | Phosphonamidate butyrophilin ligands |
| GB201810965D0 (en) | 2018-07-04 | 2018-08-15 | Univ College Cardiff Consultants Ltd | Phosphoantigen prodrug compounds |
| CA3110510A1 (en) | 2018-08-29 | 2020-03-05 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting egfr |
-
2022
- 2022-06-28 EP EP22740362.3A patent/EP4362982A1/en active Pending
- 2022-06-28 BR BR112023026735A patent/BR112023026735A2/pt unknown
- 2022-06-28 AU AU2022302784A patent/AU2022302784A1/en active Pending
- 2022-06-28 CN CN202280052486.6A patent/CN117794581A/zh active Pending
- 2022-06-28 MX MX2023014899A patent/MX2023014899A/es unknown
- 2022-06-28 IL IL309249A patent/IL309249A/en unknown
- 2022-06-28 KR KR1020247003259A patent/KR20240027761A/ko active Pending
- 2022-06-28 US US18/573,284 patent/US20240261426A1/en active Pending
- 2022-06-28 WO PCT/EP2022/067693 patent/WO2023275025A1/en not_active Ceased
- 2022-06-28 JP JP2023580402A patent/JP2024524363A/ja active Pending
- 2022-06-28 CA CA3223936A patent/CA3223936A1/en active Pending
-
2023
- 2023-12-26 CL CL2023003905A patent/CL2023003905A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024524363A5 (https=) | ||
| Valent et al. | Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML | |
| US20260035469A1 (en) | Anti-dectin-1 antibodies and methods of use thereof | |
| EP3521314B1 (fr) | Conjugues anticorps-medicament et leur utilisation en therapie | |
| CN106267188B (zh) | 小分子免疫激动剂偶联pd-1抗体的新型抗体及其在抗肿瘤中的应用 | |
| JPWO2019240287A1 (ja) | 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩 | |
| JP2022541517A5 (https=) | ||
| CN120665147A (zh) | 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐 | |
| RU2016130447A (ru) | Гетеродимерный белок il-15 и его применения | |
| JP2011058001A (ja) | 化学的に異なる末端基を含むポリ（エチレングリコール） | |
| JP2023501720A5 (https=) | ||
| CN1040204A (zh) | 细胞毒性药物结合物 | |
| JP2022530438A5 (https=) | ||
| CN87104045A (zh) | 单端孢菌烯结合物 | |
| KR20160006162A (ko) | 아마톡신 유도체 | |
| Sasaki et al. | Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses | |
| ES2502541T3 (es) | Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4) | |
| JPWO2023054714A5 (https=) | ||
| JP2015512247A5 (https=) | ||
| JP2022525400A (ja) | フルオレセインエーテルリン脂質またはフルオレセインエーテルリン脂質前駆体と併用した抗フルオレセインｃａｒ ｔ細胞に対する拮抗薬としてのフルオレセインナトリウム | |
| JP2022518771A5 (https=) | ||
| JP7783744B2 (ja) | 脂質付加タンパク質性構造の調製のためのプロセス | |
| WO2022154127A1 (ja) | 化合物またはその塩、およびそれらにより得られる抗体 | |
| CN116829573A (zh) | 化合物或其盐、及由它们得到的抗体 | |
| EP2964661B1 (en) | Metallocene compounds and labeled molecules comprising the same for in vivo imaging |